https://www.vpulsehk.com/haematology/pomalidomide-in-lenalidomide-refractory-multiple-myeloma 2026-05-14 https://www.vpulsehk.com/haematology/therapeutic-sequencing-strategy-in-multiple-myeloma 2026-05-14 https://www.vpulsehk.com/haematology/proven-benefits-of-imids-based-regimen-in-managing-multiple-myeloma 2026-05-14 https://www.vpulsehk.com/haematology/hybrid-lecture-on-management-of-relapsed-or-refractory-multiple-myeloma 2026-05-14 https://www.vpulsehk.com/haematology/management-of-relapsed-or-refractory-multiple-myeloma 2026-05-14 https://www.vpulsehk.com/haematology/the-new-all-oral-fixed-duration-regimen-for-young-and-fit-chronic-lymphocytic-leukaemia-patients 2026-05-14 https://www.vpulsehk.com/haematology/the-ever-changing-landscape-of-unresectable-hepatocellular-carcinoma 2026-05-14 https://www.vpulsehk.com/haematology/apixaban-teva%C2%AE 2026-05-14 https://www.vpulsehk.com/haematology/insure-pooled-analysis-revealed-ird-is-effective-and-safe-for-rrmm-patients-in-routine-clinical-practice 2026-05-14 https://www.vpulsehk.com/haematology/hympavzi 2026-05-14 https://www.vpulsehk.com/haematology/advancing-itp-care-rilzabrutinib%E2%80%99s-promising-results 2026-05-14 https://www.vpulsehk.com/haematology/jaypirca%C2%AE 2026-05-14